Business Description
Inhibitor Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US42278K1025
Description
Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.59 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -81.7 | |||||
| 3-Year EPS without NRI Growth Rate | -88.2 | |||||
| 3-Year FCF Growth Rate | -100 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.76 | |||||
| 9-Day RSI | 44.4 | |||||
| 14-Day RSI | 46.29 | |||||
| 6-1 Month Momentum % | 27.04 | |||||
| 12-1 Month Momentum % | 71.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.46 | |||||
| Quick Ratio | 13.46 | |||||
| Cash Ratio | 13.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 22.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.36 | |||||
| ROA % | -29.37 | |||||
| ROIC % | -1133.74 | |||||
| ROC (Joel Greenblatt) % | -21621.43 | |||||
| ROCE % | -30.33 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.21 | |||||
| Price-to-Tangible-Book | 2.28 | |||||
| EV-to-EBIT | -0.08 | |||||
| EV-to-EBITDA | -0.08 | |||||
| EV-to-FCF | -0.09 | |||||
| Price-to-Projected-FCF | 2.28 | |||||
| Price-to-Net-Current-Asset-Value | 2.28 | |||||
| Price-to-Net-Cash | 2.28 | |||||
| Earnings Yield (Greenblatt) % | -1250 | |||||
| FCF Yield % | -22.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:INTI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibitor Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.021 | ||
| Beta | -0.41 | ||
| Volatility % | 114.62 | ||
| 14-Day RSI | 46.29 | ||
| 14-Day ATR ($) | 0.006055 | ||
| 20-Day SMA ($) | 0.070195 | ||
| 12-1 Month Momentum % | 71.5 | ||
| 52-Week Range ($) | 0.0131 - 0.2999 | ||
| Shares Outstanding (Mil) | 172.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibitor Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibitor Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inhibitor Therapeutics Inc Frequently Asked Questions
What is Inhibitor Therapeutics Inc(INTI)'s stock price today?
The current price of INTI is $0.07. The 52 week high of INTI is $0.30 and 52 week low is $0.01.
When is next earnings date of Inhibitor Therapeutics Inc(INTI)?
The next earnings date of Inhibitor Therapeutics Inc(INTI) is .
Does Inhibitor Therapeutics Inc(INTI) pay dividends? If so, how much?
Inhibitor Therapeutics Inc(INTI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers